Boris Shore
President chez NORTHERN POTASH CO.
Profil
Boris Shore is currently the President of Northern Potash Co. He previously worked as the Executive Director-Research & Development at Immune Pharmaceuticals, Inc. Dr. Shore obtained his undergraduate degree from Moscow University in 1971.
Postes actifs de Boris Shore
| Sociétés | Poste | Début |
|---|---|---|
| NORTHERN POTASH CO. | President | - |
Anciens postes connus de Boris Shore
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNE PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Boris Shore
| Moscow University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NORTHERN POTASH CO. | Process Industries |
| Entreprise privées | 1 |
|---|---|
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
